ArticleClinical and experimental medicine2017
Lenalidomide potentiates CD4
Article in Clinical and experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials.Clinical and experimental medicine · 2023Pooled it
- Tregs at Diagnosis as a Potential Biomarker for Predicting High-Risk Functionality in Newly Diagnosed Multiple Myeloma.Cancer medicine · 2025Article
- Treatment of relapsed or refractory Hodgkin's lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review.Frontiers in oncology · 2025Article
- Insights into the tumor microenvironment of B cell lymphoma.Journal of experimental & clinical cancer research : CR · 2022Review
- CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression.Open life sciences · 2021Article
- Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies.Frontiers in oncology · 2021Review
- Immunomodulators in Lymphoma.Current treatment options in oncology · 2020Review
- Scientific reports concerning the impact of interleukin 4, interleukin 10 and transforming growth factor β on cancer cells.Central-European journal of immunology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have previously found that ex vivo expanded human CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.